Showing 1236 results
-
Press Release /New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
-
Press Release /Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the…
-
Press Release /The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses…
-
Press Release /Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…
-
Press Release /New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Press Release /New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
-
Press Release /Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
-
Press Release /Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas…
-
Press Release /New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
-
Press Release /Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…